Topical ivermectin 1% cream is approved in the United States, Europe and many other countries for the inflammatory "bumps and pimples" of rosacea, known as papulopustular rosacea. This article explains three things. First, why a drug best known for treating parasitic worms makes sense on the face, which comes down to the microscopic Demodex mites that live in human skin. Second, why ivermectin probably works through more than one route, including direct effects on inflammation. Third, what the clinical trials actually show, especially the large head-to-head study against topical metronidazole, which had been the standard treatment for decades. The aim is to help you understand your options well enough to have a properly informed conversation with your own doctor.
From a Japanese soil sample to the dermatology clinic
Ivermectin's origins are worth knowing. In the 1970s, Satoshi Ōmura of the Kitasato Institute in Tokyo collected soil near a golf course on Japan's Izu peninsula and isolated a bacterium, Streptomyces avermitilis. William Campbell, working at Merck in the United States, found that compounds from this organism, the avermectins, were remarkably potent against parasites. A refined derivative, ivermectin, went on to treat river blindness and lymphatic filariasis in hundreds of millions of people. Ōmura and Campbell shared the 2015 Nobel Prize in Physiology or Medicine for the work.
Many readers will find it fitting that a medicine with such reach came from an ordinary handful of earth. The created world holds resources we are only beginning to understand, and patient, careful science is how we learn to use them well. The rosacea cream is a far more modest application. It is a 1% formulation applied once daily to the face. The U.S. Food and Drug Administration approved it in late 2014 for the inflammatory lesions of rosacea in adults, and European approvals followed in 2015.
The cream should not be confused with oral ivermectin tablets. The cream is a separate product with its own dose, its own route and its own body of evidence. Oral ivermectin is not approved for rosacea, although some dermatologists have used it off-label for severe or mite-heavy cases.
What Demodex mites have to do with rosacea
Two species of mite, Demodex folliculorum and Demodex brevis, live in the hair follicles and oil glands of most adults. They are a normal part of human skin, and their numbers tend to rise with age. In most people they cause no trouble. The question has long been whether people with rosacea carry more of them, and whether that matters.
- Density is higher in rosacea. Belgian dermatologist Fabienne Forton and colleagues used a standardised skin surface biopsy in the 1990s and found markedly higher mite densities in rosacea patients. Above roughly five mites per square centimetre is now often treated as abnormal. Later systematic reviews, including a 2017 meta-analysis in the Journal of the American Academy of Dermatology, confirmed that people with rosacea are considerably more likely than controls to have high Demodex counts.
- The immune system may be reacting to the mites and their passengers. Researchers at Maynooth University in Ireland, led by Kevin Kavanagh, reported that a bacterium associated with the mites, Bacillus oleronius, produces proteins that provoke an inflammatory response in blood cells from rosacea patients. This is laboratory and patient-sample work. It is suggestive but not settled.
- Rosacea skin is primed to overreact. Work from Richard Gallo's group at the University of California, San Diego, published in Nature Medicine in 2007, showed abnormally high levels of the antimicrobial peptide cathelicidin and the enzyme that activates it in rosacea skin. Mites are one of several triggers that can set this exaggerated innate immune response in motion.
The honest summary is that the association between high mite density and papulopustular rosacea is strong and has been reproduced many times. Whether the mites cause rosacea, or flourish because rosacea skin offers them a favourable environment, is not fully resolved. Most specialists now see them as an important contributor in many patients, not the whole story. Rosacea also involves blood vessel reactivity, nerve signalling, genetics and environmental triggers such as sun, heat and alcohol.
How ivermectin works: anti-parasitic and anti-inflammatory
Ivermectin kills invertebrates by binding to glutamate-gated chloride channels in their nerve and muscle cells, which paralyses them. Mammals do not rely on these channels in the same way, which is a large part of why the drug is well tolerated in people. Applied to the skin, ivermectin reaches the follicles where Demodex live.
Human evidence that the cream lowers mite numbers comes from small clinical studies. A study from the University of Tübingen in Germany, led by Martin Schaller and published in the Journal of the European Academy of Dermatology and Venereology in 2017, examined skin from patients before and after treatment. Ivermectin reduced Demodex density and also lowered markers of inflammation in the skin. The study was small, so it supports the proposed mechanism without proving how much each effect contributes.
The second proposed action is direct suppression of inflammation, independent of any mites. In animal studies, ivermectin reduced the release of inflammatory signalling molecules such as tumour necrosis factor-alpha and interleukins. One mouse study published in 2009 showed reduced inflammatory responses to bacterial toxins, and later mouse work showed reduced allergic skin inflammation with topical ivermectin. These findings come from cell culture and animals. They are biologically plausible, but they have not been isolated cleanly in human rosacea, where the anti-mite and anti-inflammatory effects are hard to separate.
Metronidazole, by contrast, is thought to help rosacea mainly through anti-inflammatory and antioxidant effects. At the concentrations used on the skin it does little to Demodex. This difference in mechanism helps explain the trial results below.
What the clinical trials show
Approval rested on two identical phase 3 randomised, double-blind trials, reported by Linda Stein Gold and colleagues in the Journal of Drugs in Dermatology in 2014. Together they enrolled roughly 1,370 adults with moderate to severe papulopustular rosacea. Participants applied either ivermectin 1% cream or an inactive vehicle cream once daily for 12 weeks.
- The proportion rated "clear" or "almost clear" by investigators was about 38% and 40% with ivermectin, compared with about 12% and 19% with vehicle.
- Inflammatory lesion counts fell by about 75–76% with ivermectin, compared with about 50% with vehicle.
- Side effects were uncommon and similar to vehicle. The most frequent were skin burning, irritation, itching and dryness, each reported by only a small percentage of patients.
The large improvement in the vehicle groups is typical of rosacea trials. Gentle daily moisturising and the attention that comes with enrolment in a study both help. This is why comparison against a control matters so much. Extension studies of up to a year found that the benefit was maintained with continued use and that safety remained favourable.
Ivermectin compared with metronidazole
The most useful evidence for patients choosing between treatments is a direct comparison. The ATTRACT study, led by Alain Taieb of the University of Bordeaux and published in the British Journal of Dermatology in 2015, randomised 962 adults with moderate to severe papulopustular rosacea across Europe. They received either ivermectin 1% cream once daily or metronidazole 0.75% cream twice daily for 16 weeks. Investigators assessing the skin did not know which treatment each patient received.
- Inflammatory lesions fell by about 83% with ivermectin, compared with about 74% with metronidazole. The difference was statistically significant and appeared from around the third week.
- More patients on ivermectin reached "clear" or "almost clear" status, and more rated their own improvement as good or excellent.
- Tolerability was comparable, with low rates of treatment-related side effects in both groups.
In a follow-up phase, patients who had cleared were monitored after stopping treatment. Rosacea returned in both groups, which is expected with a chronic condition. However, those previously treated with ivermectin went longer on average before relapse, roughly 115 days compared with 85. One plausible explanation is that reducing the mite population leaves the skin less primed for a flare. That remains a hypothesis.
A few caveats matter. These trials were funded by the manufacturer, which is standard for drug approval and does not invalidate the results, but it is something an informed reader should know. The comparison was against twice-daily metronidazole 0.75%, not every formulation. Independent Cochrane systematic reviews of rosacea treatments, led by Esther van Zuuren, have rated the evidence for ivermectin, metronidazole and azelaic acid as reasonably strong. They suggest a modest advantage for ivermectin over metronidazole for inflammatory lesions. "Modest" is the right word. Metronidazole remains a good, well-established treatment, and some patients prefer it or respond better to it.
Practical considerations and informed choice
For papulopustular rosacea, the evidence for topical ivermectin is solid: large, well-designed human trials with clear, replicated results. Several points are useful to understand before discussing it with a physician:
- Scope. The cream targets bumps and pustules. It does little for persistent background redness or visible blood vessels. Those are managed with other approaches, including vascular laser treatment and other topical medicines.
- Time frame. Improvement often begins within a few weeks, but full benefit typically takes around three months of consistent daily use.
- Early irritation. A small number of people notice temporary stinging or a brief worsening at first. Your doctor can advise whether to continue.
- Pregnancy and breastfeeding. Very little drug is absorbed through the skin. Even so, human data in pregnancy are limited, and high-dose oral animal studies raised concerns. Because both mother and unborn child deserve protection, this is a decision to make carefully with your doctor. Other options are sometimes preferred during pregnancy.
- Other uses. Using the cream for other mite-related skin or eyelid conditions, or for other forms of rosacea, is off-label. The cream is not approved for those purposes.
Rosacea is a long-term condition. The best results usually come from a patient who understands the condition and identifies personal triggers. Gentle skin care, daily sun protection and a treatment plan worked out with a trusted physician all help. Good care respects both the evidence and the person. You have every right to ask your doctor why a treatment is recommended, what the alternatives are and what the trials found.
Key takeaway: Topical ivermectin 1% is a well-studied, generally well-tolerated treatment for the bumps and pustules of rosacea that likely works by reducing Demodex mites and calming inflammation, and in a large head-to-head trial it was modestly more effective than metronidazole, making it a reasonable option to discuss with your own physician.